

- 1 **Title:** A new method for removing artifacts from recordings of the  
2 electrically evoked compound action potential: Single-pulse  
3 stimulation
- 4 **Authors:** Jeffrey Skidmore<sup>1</sup>, Yi Yuan<sup>1</sup>, Shuman He<sup>1,2</sup>
- 5 **Affiliations:** <sup>1</sup>Department of Otolaryngology – Head and Neck Surgery, The  
6 Ohio State University, 915 Olentangy River Road, Columbus, OH  
7 43212, USA  
8 <sup>2</sup>Department of Audiology, Nationwide Children’s Hospital, 700  
9 Children’s Drive, Columbus, OH 43205, USA
- 10 **Correspondence:** Jeffrey Skidmore, PhD  
11 Eye and Ear Institute  
12 Department of Otolaryngology – Head and Neck Surgery  
13 The Ohio State University  
14 915 Olentangy River Road, Suite 4000  
15 Email: Jeffrey.Skidmore@osumc.edu
- 16 **Declarations of Interest:** None.
- 17 **Author Contributions:** Jeffrey Skidmore: Conceptualization, Methodology,  
18 Investigation, Writing - Original draft preparation, Visualization. Yi  
19 Yuan: Investigation, Writing – Review and editing. Shuman He:

20 Funding acquisition, Conceptualization, Supervision, Writing -  
21 Review and editing.

22 **Source of Funding:** This work was supported by the National Institutes of Health [grant  
23 numbers 1R01 DC016038, 1R01 DC017846, R21 DC019458].

24 **Acknowledgments:** The authors thank Ryan Melman (Senior Research Engineer,  
25 Cochlear Ltd.) for an insightful discussion about operational  
26 amplifiers and artifact removal methods

27 **ORCID:** Jeffrey Skidmore: 0000-0002-6015-7574

28

## 29 **ABSTRACT**

30 This report presents a new method for removing electrical artifact contamination  
31 from the electrically evoked compound action potential (eCAP) evoked by single cathodic-  
32 leading, biphasic-pulse stimulation. The development of the new method is motivated by  
33 results recorded in human cochlear implant (CI) users showing that the fundamental  
34 assumption of the classic forward masking artifact rejection technique is violated in up to  
35 45% of cases tested at high stimulation levels when using default stimulation parameters.  
36 Subsequently, the new method developed based on the discovery that a hyperbola best  
37 characterizes the artifacts created during stimulation and recording is described. The  
38 eCAP waveforms obtained using the new method are compared to those recorded using  
39 the classic forward masking technique. The results show that eCAP waveforms obtained

40 using both methods are comparable when the fundamental assumption of the classic  
41 forward masking technique is met. In contrast, eCAP amplitudes obtained using the two  
42 methods are significantly different when the fundamental assumption of the classic  
43 forward masking technique is violated, with greater differences in the eCAP amplitude for  
44 greater assumption violations. The new method also has excellent test-retest reliability  
45 (Intraclass correlation  $> 0.98$ ). Overall, the new method is a viable alternative to the  
46 classic forward masking technique for obtaining artifact-free eCAPs evoked by single-  
47 pulse stimulation in CI users.

48 **Key Words:** cochlear implants, auditory nerve, electrically evoked compound action  
49 potential

## 50 INTRODUCTION

51           The electrically evoked compound action potential (eCAP) measured at the  
52 auditory nerve is a summed response generated by a group of auditory nerve fibers  
53 (ANFs) responding synchronously to electrical stimulation [1, 2]. This near-field response  
54 can be recorded directly from a patient's cochlear implant (CI) using the telemetry  
55 functions implemented in the CI and the commercial software provided by the CI  
56 manufacturer. The eCAP has been shown to be useful for estimating the physiological  
57 status of the auditory nerve [3-9]. These estimates of the physiological status of the  
58 auditory nerve may have clinical benefits such as longitudinal monitoring of neural health  
59 [10, 11], implant fitting [12-14] and explaining variance in speech perception performance  
60 among CI users [9, 15-18].

61           The primary challenge in recording eCAPs is the presence of unwanted voltages  
62 (i.e., electrical artifacts) that contaminate and obscure the neural response. The largest  
63 artifact is caused by decaying charges produced during stimulation (i.e., stimulation  
64 artifact) due to capacitors in the CI [19] and the capacitive properties of the electrode–  
65 electrolyte interface [20]. The stimulation artifact increases with stimulation level and is  
66 typically several orders of magnitude larger than the eCAP. Another artifact comes from  
67 the switching of the recording amplifier during the measurement process (i.e., recording  
68 artifact). While smaller than the stimulation artifact, the recording artifact is sufficiently  
69 large that it can contaminate the eCAP response, especially at stimulation levels near the  
70 eCAP threshold. Therefore, techniques to remove or reduce the stimulation and recording  
71 artifacts from eCAP recordings are necessary.

72           Several artifact rejection techniques have been used or proposed over the past  
73 few decades for recording eCAPs in response to single-pulse stimulation. These  
74 techniques include the classic two-pulse forward masking [FwdMsk; 1], alternating  
75 polarity, and subthreshold template subtraction [21], along with more recent techniques  
76 such as precision triphasic-pulse stimulation [22], independent component analysis [23],  
77 and multi-curve-fitting [24]. The strengths, weaknesses, and limitations of each technique  
78 have been described previously [e.g., 2, 23, 25, 26].


79           In recent years, FwdMsk has by far been the most commonly used artifact rejection  
80 technique for eCAP recordings, especially in CI users [e.g., 3-5, 7-9, 12, 15, 27, 28-32].  
81 However, while the important considerations and limitations of FwdMsk are well known in  
82 theory, it is difficult to choose appropriate stimulation parameters in practice because of  
83 the challenges in verifying the underlying assumptions of this technique when collecting  
84 eCAP data. Therefore, as the motivation for the development of the method described in  
85 this report, we first review the theoretical basis and demonstrate the limitations of FwdMsk  
86 before describing the new method.

## 87 **TWO-PULSE FORWARD MASKING**

88           The classic two-pulse forward masking technique [1] has been used in many  
89 studies over the last few decades for recording eCAPs in CI users. The method creates  
90 templates of the stimulation and recording artifacts by recording voltages in response to  
91 four stimuli. The first stimulus is a single pulse (i.e., probe pulse) which results in a  
92 recorded voltage trace ('A' trace) that includes the probe stimulation artifact, the recording

93 artifact, and the eCAP evoked by the probe. The second stimulus is the same as the first  
94 stimulus with the addition of a masker pulse which precedes the probe pulse by a  
95 specified inter-stimulus interval (i.e., masker-probe interval, MPI). In addition to the  
96 masker stimulation artifact and the neural response evoked by the masker pulse, the  
97 recorded voltage trace ('B' trace) consists of the probe stimulation artifact, the recording  
98 artifact, and potentially an eCAP response evoked by the probe pulse. Ideally, a relatively  
99 high masker stimulation level compared to the probe stimulation level and a short MPI  
100 are used to set the neurons in an absolute refractory state so that there is no neural  
101 response to the probe pulse. This is the fundamental assumption of FwdMsk. The third  
102 stimulus is the same as the second stimulus without a probe pulse. This single (masker)  
103 pulse results in a recorded voltage trace ('C' trace) that contains the masker stimulation  
104 artifact, the recording artifact, and the neural response evoked by the masker pulse. The  
105 fourth stimulus is a zero-amplitude stimulation that provides a template of the recording  
106 artifact ('D' trace) caused by the switching of the recording amplifier. After the four traces  
107 are recorded, a template waveform ('T' waveform) that consists of the probe stimulation  
108 artifact, the recording artifact, and any eCAP response evoked by the probe pulse in the  
109 second recording, is derived by adding the fourth recording to the difference between the  
110 second and third recordings (i.e.,  $T = B - C + D$ ). Finally, the eCAP waveform ('E'  
111 waveform) is obtained by subtracting this artifact template from the first recording (i.e.,  $E$   
112  $= A - T$ ). Therefore, any neural response to the probe pulse included in the 'B' trace is  
113 also in the artifact template 'T' and alters the derived eCAP waveform 'E'. This method is  
114 illustrated in Figure 1 for supra-threshold stimulation levels. Examples of each recorded

115 trace and derived waveform are shown in Figure 2 for one case in which the artifact  
 116 template is free of neural response (i.e., complete masking) and one case in which the  
 117 artifact template has a neural response (i.e., incomplete masking).




\* Probe response depends upon effect of preceding masker pulse

118

119 **Figure 1.** Illustration of the classic two-pulse forward masking artifact rejection technique  
 120 for removing artifacts from recordings of the electrically evoked compound action  
 121 potential (eCAP).

122



123

124 **Figure 2.** Examples of recorded traces and derived waveforms obtained using the classic  
 125 two-pulse forward masking artifact rejection technique for one case in which the artifact  
 126 template is free of neural response (left panel) and one case in which the artifact template  
 127 has a neural response (right panel).

128

129 As stated above, FwdMsk only produces an artifact-free eCAP waveform if there  
 130 is no neural response to the probe pulse when preceded by a masking pulse. The two  
 131 primary factors that affect the validity of this assumption are the stimulation level of the  
 132 masker pulse relative to the stimulation level of the probe pulse and the duration of the  
 133 MPI. The considerations and implications of each of these two factors are reported below.



### 134 **Stimulation Level of Masker Pulse**


135 In FwdMsk, the masker pulse must be sufficiently large to activate the target ANFs.  
136 Otherwise, the neurons that are not activated by the masker pulse may be activated by  
137 the probe pulse that follows. This incomplete masking is manifest by neural response  
138 being present in the 'B' trace, as observed in the right panel of Figure 2, and results in a  
139 reduced eCAP compared to the fully-masked condition. A difference in stimulation level  
140 between the masker pulse and the probe pulse (i.e., masker offset) of +10 current levels  
141 (CL) has been proposed to be sufficient for producing the desired masking effect [33] and  
142 is a frequently used masker offset [e.g., 4, 6, 8, 9, 12, 27-30].

### 143 **Duration of Masker-probe Interval**

144 In FwdMsk, the MPI must be equal or shorter than the absolute refractory period  
145 (ARP) of the target neurons so that all neurons activated by the masker pulse will not  
146 respond to the probe pulse. Otherwise, some neurons activated by the masker pulse may  
147 have recovered sufficiently to respond to the probe pulse and generate an action  
148 potential. The fraction of neurons that respond to the probe pulse is influenced by at least  
149 two factors: the difference between the MPI and the ARP, and the speed of recovery  
150 during the relative refractory period (RRP). More neurons respond to the probe pulse  
151 when there are larger differences between the MPI and the ARP and when there is faster  
152 recovery during the RRP. Therefore, there are larger neural responses in the artifact  
153 template with larger differences between the MPI and the ARP, as shown in the middle  
154 panel of Figure 3. Additionally, phase-shifts in the artifact templates relative to the probe-

155 only recordings, likely due to cross-fiber variability in refractory recovery times [34],  
 156 change the morphology of the derived eCAP waveforms. As observed in the bottom panel  
 157 of Figure 3, there are increasing changes in peak latencies and peak amplitudes relative  
 158 to the fully-masked condition (i.e., MPI = 300  $\mu$ s) with increasing time between the MPI  
 159 and the ARP. Therefore, eCAP amplitudes and peak latencies obtained using FwdMsk  
 160 are not accurate if the MPI is longer than the ARP, with larger errors occurring for larger  
 161 differences between the MPI and the ARP.

162



163

164 **Figure 3.** Recorded traces to probe-only stimulation (top panel) and derived artifact  
165 templates and eCAP waveforms (middle and bottom panel, respectively) obtained using  
166 the classic two-pulse forward masking artifact rejection technique for single-pulse stimuli  
167 with various masker-probe intervals at one electrode location in one adult cochlear  
168 implant user. The absolute refractory recovery period estimated at this electrode location  
169 (i.e.,  $t_0$ ) is provided in the corner of the bottom panel.

170

171 In practice, it is not straightforward to verify whether the MPI is set correctly when  
172 collecting eCAP data in individual CI users because it requires an estimate of the ARP.  
173 Therefore, it is not well-known how often the assumption of complete masking is met  
174 when using FwdMsk. Moreover, recovery from refractoriness is affected by the stimulation  
175 level, with faster recovery occurring at higher stimulation levels [34, 35]. At low stimulation  
176 levels and short MPIs (i.e.,  $< 300 \mu\text{s}$ ), a facilitatory effect could occur in which neurons not  
177 activated by the first pulse could be activated by the second pulse due to temporal  
178 integration of the charge [36]. The strongest facilitation effect is observed when the first  
179 pulse is near the eCAP threshold [35, 37], and the effect increases for shorter MPIs [38].  
180 Refractory recovery periods and facilitatory effects are also influenced by the health of  
181 the ANFs [39, 40]. Therefore, the optimal MPI for recording eCAPs using FwdMsk could  
182 vary across CI users, electrode locations and stimulation levels.

183 **Absolute Refractory Periods at High Stimulation Levels**

184           As discussed previously, FwdMsk is dependent on the MPI being within the ARP  
185 of the target ANFs. An MPI of 400  $\mu$ s has been used frequently in eCAP studies in CI  
186 users with Cochlear™ Nucleus® or Advanced Bionics devices [e.g., 3-5, 7-9, 12, 15, 25,  
187 27, 28-32, 40]. Therefore, it is important to understand whether 400  $\mu$ s is generally within  
188 the ARP, and therefore, an appropriate MPI for recording eCAPs in CI users. The ARP  
189 (i.e., the time period following stimulation in which none of the target neurons could  
190 generate an action potential) can be estimated by fitting an exponential decay function to  
191 the eCAP refractory recovery function as has been done in previously published studies  
192 [e.g., 8, 9, 19, 40, 41]. The eCAP refractory recovery function is obtained using the  
193 modified template subtraction technique [26]. The modified template subtraction  
194 technique is a modification of FwdMsk that enables the measurement of artifact-free  
195 eCAPs obtained in a paired-pulse stimulation paradigm with various MPIs. Importantly,  
196 the default reference MPI used in the modified template subtraction technique is 300  $\mu$ s,  
197 instead of 400  $\mu$ s used in FwdMsk. Using the modified template subtraction technique,  
198 Morsnowski, et al. (41) reported a median ARP of 390  $\mu$ s across 84 electrode locations  
199 measured in 14 CI users when evaluated at the participant's maximum comfort level (i.e.,  
200 C level). Therefore, more than half of the electrode locations in their study had an ARP of  
201 less than 400  $\mu$ s when measured at C level.


202           To confirm the finding reported in Morsnowski, et al. (41), we evaluated ARPs at  
203 473 electrode locations across 80 pediatric and adult CI users (Pediatrics: 27 participants,  
204 38 ears, 127 electrode locations; Adults: 53 participants, 62 ears, 346 electrode  
205 locations). All participants used a Cochlear™ Nucleus® device (Cochlear Ltd.) and had

206 normal inner ear anatomy. eCAP recordings were obtained using the Advanced Neural  
207 Response Telemetry function implemented in the Custom Sound EP (v. 5.1, v.5.2 or  
208 v.6.0) commercial software (Cochlear Ltd, Sydney, NSW, Australia) using the modified  
209 template subtraction technique [26]. Both the masker and the probe were symmetric,  
210 cathodic-leading, biphasic pulses with an interphase gap of 7  $\mu$ s and a pulse phase  
211 duration of 25  $\mu$ s/phase. The masker and the probe were presented to the test electrode  
212 at the participants' C level and 10 CL below C level, respectively, to obtain a masker offset  
213 of +10 CL. eCAPs were recorded as the MPI was systematically increased from 100  $\mu$ s  
214 to 10 ms. Other recording parameters included a 122- $\mu$ s recording delay, an amplifier  
215 gain of 50 dB, and a sampling rate of 20,492 Hz. Estimates of the ARP (i.e.,  $t_0$ ) were  
216 obtained by fitting a decaying exponential function to the eCAP amplitudes plotted as a  
217 function of MPI as done in our previous studies [8, 9, 40]. Any estimates of the ARP below  
218 300  $\mu$ s were excluded as poor fits, as was done by Morsnowski, et al. (41), because of  
219 the use of 300  $\mu$ s as the reference MPI in the modified template subtraction technique. In  
220 total, 16/473 (3.4%) of the estimates were excluded (Pediatrics: 3/127 = 2.4%; Adults  
221 13/346 = 3.8%).

222         The ARP estimates measured in pediatric and adult CI users are shown separately  
223 in Figure 4. The result of a Mann-Whitney U test showed that estimated ARPs were  
224 significantly longer in the pediatric CI users than in the adult CI users ( $U = 17422$ ,  $p =$   
225  $0.010$ ). This can be explained, at least in part, by the difference in stimulation levels used  
226 in these two participant groups. Specifically, the result of a Mann-Whitney U test showed  
227 that the stimulation level was significantly lower in the pediatric CI users than in the adult

228 CI users ( $U = 16088$ ,  $p < 0.001$ ). There was a significant negative correlation between  
229 estimated ARP and stimulation level for both patient populations (Pediatrics:  $N = 124$ ,  $r =$   
230  $-0.28$ ,  $p = 0.002$ ; Adults:  $N = 333$ ,  $r = -0.31$ ,  $p < 0.001$ ), indicating shorter ARPs at higher  
231 stimulation levels. This is consistent with the results of other studies [34, 35]. More  
232 importantly, 192/457 (42.0%) of the estimated ARPs were less than 400  $\mu\text{s}$  (Pediatrics:  
233 41/124 = 33.1%; Adults: 151/333 = 45.4%). These data clearly indicate that FwdMsk is  
234 not sufficient for removing artifacts from eCAP recordings in many cases due to violated  
235 underlying assumptions.

236



237

238 **Figure 4.** Violin plots of absolute refractory periods estimated from electrically evoked  
239 compound action potential refractory recovery functions measured at 127 electrode  
240 locations in 27 pediatric cochlear implant (CI) users (blue circles) and 346 electrode  
241 locations in 53 adult CI users (red circles). The white circle represents the median value.  
242 The black box represents the interquartile range (IQR), and the vertical black lines extend  
243 to the value that is the furthest from the median while still being within  $1.5 \times \text{IQR}$  from the  
244 lower or upper quartile. The dashed horizontal line at  $400 \mu\text{s}$  illustrates the default  
245 masker-probe interval used in the forward masking technique for single-pulse stimulation.

246

247 To date, a viable alternative to traditional artifact rejection techniques has not been  
248 identified. As a step toward addressing this issue, we recently developed a new method  
249 for removing artifacts from eCAP recordings measured for cathodic-leading stimulation.

## 250 **METHODS**

### 251 **Study Participants**

252 The development and validation of the new method for removing artifacts from  
253 eCAP recordings was performed in a subset of the 80 pediatric and adult CI users in  
254 whom estimates of the ARP were obtained at multiple electrode locations (see subsection  
255 Absolute Refractory Periods at High Stimulation Levels above). Specifically, this subset  
256 of CI users included 17 pediatric and adult CI users (8 Female, 9 Male) ranging in age  
257 from 16.9 to 84.0 years (mean: 53.5 years, SD: 22.1 years). Participants A3, A5, and P2  
258 were implanted bilaterally, and each ear was tested separately in this study. Additional

259 eCAPs were measured at the two electrode locations with the largest difference in the  
260 estimated ARP in each of the 20 ears tested. Across all ears tested, there were 20  
261 electrodes tested with an estimated ARP less than 400  $\mu$ s and 20 electrodes tested with  
262 an estimated ARP greater than 400  $\mu$ s. Demographic information for each of the 17 study  
263 participants, along with the estimated ARP obtained at each of the electrodes tested in  
264 this study, are provided in Table 1. Written informed consent and/or verbal assent was  
265 obtained from all study participants and/or their legal guardians at the time of data  
266 collection. The study was approved by the Biomedical Institutional Review Board (IRB) at  
267 The Ohio State University (IRB study #: 2017H0131).

268



269

270 **TABLE 1.** Demographic information of all study participants. CI24RE (CA), Freedom  
 271 Contour Advance electrode array; SHL, sudden hearing loss; AN, acoustic neuroma;  
 272 EVA, enlarged vestibular aqueduct; ARP, absolute refractory period.

Participant ID	Sex	Ear tested	Age (years)	Internal device and electrode array	Etiology of hearing loss	Electrodes tested	Estimated ARP ( $\mu$ s)
A1	M	L	60s	CI512	SHL	3, 9	392, 392
A2	M	L	60s	CI512	Meniere's	15, 18	378, 380
A3	F	L	60s	CI24RE (CA)	Hereditary	3, 21	330, 377
A3	F	R	60s	CI24RE (CA)	Hereditary	9, 15	353, 309
A4	F	L	30s	CI24RE (CA)	Trauma	3, 9	414, 464
A5	F	L	50s	CI532	Unknown	4, 15	656, 349
A5	F	R	50s	CI24RE (CA)	Unknown	9, 21	485, 513
A6	F	R	50s	CI24RE (CA)	Hereditary	3, 21	387, 454
A7	M	L	60s	CI632	Unknown	3, 9	579, 429
A8	M	L	60s	CI532	AN	9, 15	501, 375
A9	F	R	80s	CI532	Hereditary	3, 7	366, 359
A10	F	L	30s	CI532	Unknown	3, 9	554, 903
A11	F	R	50s	CI532	Hereditary	12, 15	357, 358
A12	M	R	80s	CI632	Unknown	3, 9	441, 447
A13	F	L	50s	CI632	Unknown	3, 15	944, 713
A14	M	L	70s	CI632	Unknown	15, 21	389, 358
P1	M	R	10s	CI24RE (CA)	Connexin	4, 12	463, 380
P2	M	L	10s	CI24RE (CA)	Usher	14, 21	342, 350
P2	M	R	10s	CI24RE (CA)	Usher	2, 9	413, 467
P3	M	L	10s	CI24RE (CA)	EVA	12, 21	1321, 403

273

274

275

276

277

## 278 **eCAP Measurements**

279 All eCAPs were obtained following the same procedures as those used in our  
280 previous studies [e.g., 8, 9, 40] and using the Custom Sound EP (v. 5.1 or 6.0) software  
281 interface (Cochlear Ltd, Sydney, NSW, Australia). The stimulus was one cathodic-  
282 leading, biphasic pulse with an interphase gap of 7  $\mu$ s and a pulse phase duration of 25  
283  $\mu$ s/phase. The stimulus was presented at the participants' C level for all electrodes tested  
284 and repeated four times for calculating test-retest reliability. All stimuli were presented in  
285 a monopolar-coupled stimulation mode to individual CI electrodes via an N6 sound  
286 processor connected to a programming pod. For all eCAP measurements, the recording  
287 window was set to 64 samples (3,123  $\mu$ s), the longest recording window allowed in  
288 Custom Sound EP. Additional recording parameters were a 122- $\mu$ s recording delay, an  
289 amplifier gain of 50 dB, a sampling rate of 20,492 Hz, and 50 sweeps per averaged eCAP  
290 response.

## 291 **Hyperbola-fitting Artifact Subtraction Method**

292 The hyperbola-fitting artifact subtraction method (HyperFit) was developed to  
293 address the limitations of FwdMsk. This method is based on the discovery that the  
294 waveform of the combined stimulation and recording artifacts is best characterized as a  
295 hyperbola for stimulation at a single electrode location (e.g., co-located masker and  
296 probe). Therefore, we first discuss the characterization of the artifact template as a  
297 hyperbola. We then provide a conceptual overview of the new method and detail how the  
298 method was implemented in this study.


299 Artifact Characterization for Co-located Masker and Probe

300 We investigated the morphology of the combined stimulation and recording  
301 artifacts (i.e., artifact template) by analyzing the 100 recordings obtained using FwdMsk  
302 at electrode locations where the estimated ARP at C level was greater than 400  $\mu$ s.  
303 Additionally, the masker offset was +10 CL for each of these recordings. Therefore, the  
304 artifact template obtained via FwdMsk for each of these recordings should be free of  
305 neural responses. For each recording, the artifact template was calculated by adding and  
306 subtracting the traces obtained using FwdMsk (see Figure 1). Representative artifact  
307 templates obtained at seven electrode locations in five CI users are shown in Figure 5A.

308

309

310



311

312 **Figure 5.** Representative artifact templates derived from recordings of the electrically  
 313 evoked compound action potential (eCAP) using the classic two-pulse forward  
 314 masking artifact rejection technique. Panel A: Artifact templates (colored traces)  
 315 derived from eCAP recordings obtained at seven electrode locations in five cochlear  
 316 implant users. Panel B: The results of linear regression using only the section of  
 317 artifact template occurring after 2200  $\mu\text{s}$  for three of the artifact templates shown in  
 318 Panel A.

319

320 As can be seen in the figure, the artifact templates decrease monotonically with a  
321 rapid decay at the beginning of the recording window and then gradually transition to a  
322 line with a negative slope at the end of the recording window for all stimulation levels. To  
323 verify that the final section of the artifact templates reached a linear asymptote, linear  
324 regression was performed on the section of the artifact template occurring after 2200  $\mu$ s.  
325 The results of linear regression for sections of three of the artifact templates shown in  
326 Figure 5A are provided in Figure 5B. Each subpanel shows a significant negative slope,  
327 and the residuals appear to be normally distributed without any systematic bias. Results  
328 of linear regression revealed that the slope was negative and significant ( $p \leq 0.008$ ), and  
329 the residuals were normally distributed as verified by the Anderson-Darling test ( $p \geq 0.$   
330 538) for all 100 eCAP recordings after correcting for multiple comparisons using the False  
331 Discovery Rate [42]. Therefore, these results confirmed that the artifact template reached  
332 a slanted asymptote for all recordings.

333 These features observed in the artifact template (i.e., rapid initial decay and  
334 slanted asymptote) can be well described by a hyperbola. A hyperbola is a smooth curve  
335 that is described by the rational function  $y = ax + b + c(x + d)^{-1}$ . This function has a  
336 vertical asymptote at  $x = -d$  and a slanted asymptote at  $y = ax + b$ . Therefore,  
337 parameter  $d$  of the function corresponds to the vertical asymptote that bounds the rapid  
338 initial decay, while parameters  $a$  and  $b$  correspond to the slope and the vertical offset of  
339 the line at the latter end of the recording, respectively. Parameter  $c$  reflects the speed of  
340 the transition between those two portions of the recording, where a larger value of  $c$

341 corresponds to a slower transition. A summary of the parameter values obtained when  
 342 fitting a hyperbola each of the 100 artifact templates is provided in Table 2.

343

344

345 **Table 2.** Summary of the parameter values obtained when fitting a hyperbola to artifact  
 346 templates.

	a ( $\mu\text{V}/\mu\text{s}$ )	b ( $\mu\text{V}$ )	c ( $\mu\text{V}\cdot\mu\text{s}$ )	d ( $\mu\text{s}$ )
Minimum	-0.051	-2,457.6	18,663	-119.4 <sup>347</sup>
Maximum	-0.002	-94.3	205,970	-58.1 <sup>348</sup>
Mean	-0.019	-757.8	67,631	-96.1 <sup>349</sup>
Standard deviation	0.016	618.4	50,992	18.5 <sup>350</sup>

351

352

353 To verify that a hyperbola best describes the artifact template, we compared the  
 354 goodness of fit (i.e.,  $R^2$ ) obtained with a hyperbola for all 100 recordings to the goodness  
 355 of fit obtained with two other functions that have been proposed to represent the artifact  
 356 template: a two-component exponential function  $y = ae^{bx} + ce^{dx} + e$  [24] and a combined  
 357 exponential and linear function  $y = ae^{bx} + cx + d$  [43]. The  $R^2$ s were not normally  
 358 distributed for any of the three functions, so we report medians and interquartile ranges  
 359 instead of means and standard deviations. A Friedman test was also conducted to  
 360 determine whether the  $R^2$  differed between the three function fittings. As expected, the

361  $R^2$  was higher for the hyperbola than for the other two functions (Hyperbola: median =  
362 0.999, IQR = 0.001; Two-component exponential function: median = 0.671, IQR = 0.578;  
363 Combined exponential and linear function: median = 0.991, IQR = 0.004). The result of  
364 the Friedman test showed a significant difference between the three fitting functions  
365 ( $\chi^2_{2,198} = 123.5$ ,  $p < 0.001$ ). All post hoc comparisons were also significant ( $p < 0.001$  for  
366 all comparisons). Therefore, these results confirm that a hyperbola characterizes the  
367 artifact template better than the other two functions.

#### 368 Conceptual Overview of the Hyperbola-fitting Artifact Subtraction Method


369 The method is illustrated in Figure 6 and entails creating an artifact template for  
370 individual recordings by fitting a hyperbola to the probe-only recording trace with greater  
371 fitting-weight given to data points in the sections of the recording in which little or no neural  
372 response is present. Specifically, greater fitting-weight is given to the data points in the  
373 recording in which the time from the onset of the probe stimulus is less than 200  $\mu\text{s}$  or  
374 greater than 2200  $\mu\text{s}$ . These time periods are chosen because the neural response is  
375 assumed to be very small and/or not present in these time periods. Even if there is some  
376 neural response in recording within the first 200  $\mu\text{s}$  after the onset of the probe stimulus,  
377 the stimulation artifact is much larger than the neural response. A cutoff time of 2200  $\mu\text{s}$   
378 is chosen as a conservative estimate of the time point when the eCAP response has  
379 ended, which has been estimated up to 1300  $\mu\text{s}$  [44, 45]. Moreover, this portion of the  
380 recording window is characterized by a line with a negative slope (see previous  
381 subsection). Therefore, we assume that the neural response should be very small or not  
382 present in that portion of the recording. After fitting the hyperbola, the hyperbola (i.e.,

383 artifact template) is subtracted from the probe-only recording to give the artifact-free  
384 eCAP waveform.

385

386

387



389 **Figure 6.** Illustration of the hyperbola-fitting artifact subtraction technique. The electrically  
390 evoked compound action potential (eCAP) waveform (black line, right panel) is derived  
391 by subtracting the hyperbola (red line, left panel) that is fit to the probe-only recording  
392 (black line, left panel) with greater fitting-weight given to data points within the time  
393 periods in which little or no neural response is present (lightly shaded regions, left panel).

394

395

396

397



## 398 Implementation of the Hyperbola-fitting Artifact Subtraction Method

399           The new method was implemented in this study in a series of three steps using  
400 MATLAB (v. 2021b) software (MathWorks Inc.).

### 401 *Step 1: Re-sample the probe-only recording at 102,460 Hz*

402           The default sampling frequency used in Custom Sound EP is 20,492 Hz, which  
403 corresponds to a sampling period of 48.8  $\mu$ s. Therefore, for stimulation and recording  
404 parameters used in this study (i.e., pulse phase duration = 25  $\mu$ s/phase, interphase gap  
405 = 7  $\mu$ s, recording delay = 122  $\mu$ s), only one sample was obtained within the first 200  $\mu$ s  
406 after the stimulus onset. Specifically, the first sample occurred at 179  $\mu$ s and the second  
407 sample occurred at 227.8  $\mu$ s after the stimulus onset. Therefore, the probe-only recording  
408 was resampled at 102,460 Hz (i.e., 5x the original sampling rate) using spline interpolation  
409 to obtain a sampling resolution of 9.8  $\mu$ s, which provided three data points within the first  
410 200  $\mu$ s after the stimulus onset. The resampling was done using the 'spline' method of  
411 the 'interp1' MATLAB function which uses cubic spline interpolation.

### 412 *Step 2: Fit the hyperbola to the re-sampled waveform with custom weighting values*

413           In typical function-fitting, each data point is given equal weight in the least-squares  
414 error minimization. However, due to the presence of both artifact and neural response in  
415 the probe-only recordings, it was necessary to use custom weighting values to emphasis  
416 the fitting to the portions of the recording in which little or no neural response is present.  
417 Specifically, the data points in the recording in which the time from stimulus onset is less  
418 than 200  $\mu$ s or greater than 2200  $\mu$ s were given the standard weight of 1, while all other

419 data points were given a weight of 0.015. This weighting emphasized the fitting of the  
420 vertical asymptote (i.e., fitting-parameter  $d$ ) and the slanted asymptote (i.e., fitting-  
421 parameters  $a$  and  $b$ ) while also allowing the remaining data points, even if they contain  
422 substantial neural response, to guide the transition between the asymptotes (i.e., fitting-  
423 parameter  $c$ ). The function fitting was done using the 'fit' function of MATLAB's Curve  
424 Fitting Toolbox. Other than the custom weighting values, all other fitting options were the  
425 default options.

426 *Step 3: Subtract the hyperbola from the original probe-only recording*

427       Importantly, this subtraction is performed only at the original sampling times.  
428 Therefore, this method does not modify the probe-only recording when deriving the eCAP  
429 waveform. Rather, the up-sampling simply creates more data points for the fitting process.

### 430 **Comparison between Forward Masking and New Method**

431       In theory, eCAP amplitudes obtained using FwdMsk and HyperFit should be similar  
432 in cases where the masker offset is sufficiently large, the estimated ARP is greater than  
433 the MPI, and the masker and probe pulses are presented at the same electrode location.  
434 In contrast, a difference in eCAP amplitudes obtained using the two methods would be  
435 expected if the estimated ARP were less than the MPI, with greater differences in eCAP  
436 amplitudes observed for greater differences between the estimated ARP and the MPI.  
437 We tested these theoretical expectations by comparing eCAP amplitudes obtained using  
438 FwdMsk and HyperFit at each of the 40 electrodes tested.

### 439 **Statistical Analyses**

440           The theoretical expectations were assessed using Linear Mixed-effects Models  
441 (LMMs). Specifically, the effect of the artifact removal method on the eCAP amplitude  
442 was assessed with a LMM where the eCAP amplitude was the outcome variable, the  
443 artifact removal method was the fixed effect, and participant, electrode location and test  
444 ear (i.e., Left/Right) were random effects. One LMM was used with the data for which the  
445 estimated ARP was less than 400  $\mu\text{s}$  and one used with the data for which the estimated  
446 ARP was greater than 400  $\mu\text{s}$  according to the theoretical expectations. A third LMM  
447 assessed the effect of the estimated ARP on the difference in the eCAP amplitude  
448 obtained using the two artifact removal methods when the estimated ARP was less than  
449 400  $\mu\text{s}$ . For this LMM, the difference in the eCAP amplitude obtained using the two  
450 methods (FwdMsk – HyperFit) was the outcome variable, the estimated ARP was the  
451 fixed effect, and participant, electrode location and test ear were random effects.

452           The test-retest reliability of the fitting-parameters and the eCAP amplitudes  
453 obtained using HyperFit for repeated measurements of the same stimulus were evaluated  
454 with the intraclass correlation coefficient (ICC). ICC(2,1) was chosen as the metric of  
455 interest because it quantifies the level of agreement across trials [46]. All statistical  
456 analyses for this study were performed using MATLAB (v. 2021b) software (MathWorks  
457 Inc.).


## 458 **RESULTS AND DISCUSSION**

459           Representative eCAP waveforms derived using FwdMsk and HyperFit are shown  
460 in the bottom panels of Figure 7 and Figure 8 from recordings at three electrode locations

461 at which the estimated ARP was greater than 400  $\mu\text{s}$  and less than 400  $\mu\text{s}$ , respectively.  
 462 The probe-only recordings and the artifact templates from which the eCAP waveforms  
 463 were derived are shown in the top panels of each figure.

464


465



466

467 **Figure 7.** Representative probe-only recordings and artifact templates (top  
 468 panels), along with electrically evoked compound action potential (eCAP) waveforms  
 469 (bottom panels), obtained using the classic two-pulse forward masking artifact rejection  
 470 technique (FwdMsk) and the new hyperbola-fitting artifact subtraction technique  
 471 (HyperFit) at three electrode locations at which the estimated absolute refractory period  
 472 (i.e.,  $t_0$ ) was greater than 400  $\mu\text{s}$ .

473



474

475

476

477

478

479

480

481

482

483

484

485

486

**Figure 8.** Representative probe-only recordings and artifact templates (top panels), along with electrically evoked compound action potential (eCAP) waveforms (bottom panels), obtained using the classic two-pulse forward masking artifact rejection technique (FwdMsk) and the new hyperbola-fitting artifact subtraction technique (HyperFit) at three electrode locations at which the estimated absolute refractory period (i.e.,  $t_0$ ) was less than 400  $\mu\text{s}$ .

As observed in Figure 7, the eCAP waveforms derived using FwdMsk and HyperFit were comparable when the estimated ARP was greater than 400  $\mu\text{s}$ . Most importantly, the difference in eCAP amplitudes obtained using the two methods was less than 5  $\mu\text{V}$ , which is within the noise floor of these devices [47]. In contrast, there were large differences in eCAP amplitudes obtained using these two methods when the estimated

487 ARP was smaller than 400  $\mu$ s, as observed in Figure 8. The primary reason for the larger  
488 eCAP amplitudes when using FwdMsk was the phase difference/shift between the neural  
489 response to the probe pulse in the masker + probe stimulation condition and the neural  
490 response included in the probe-only recording. Therefore, the neural response was  
491 present in the artifact template derived using FwdMsk, which altered the morphology of  
492 the derived eCAP waveform.


493 One difference in the eCAP waveforms obtained using the FwdMsk and HyperFit  
494 observed in Figure 7 and Figure 8 is the difference in plateau voltage of the eCAP  
495 waveform (i.e., vertical offset). The characteristics of the operational amplifiers included  
496 in the CI contributes, at least partially, to this vertical offset as well as the variability in the  
497 observed offset across study participants and test electrodes. Specifically, the telemetry  
498 circuitry includes an auto-zero amplifier which sets the zero/reference point shortly before  
499 the first voltage sample is acquired in each measurement trace. All subsequent samples  
500 of that trace are measured relative to that zero/reference point. Since each measurement  
501 trace has its own reference point, the vertical offset between traces is not consistent. The  
502 eCAP waveform obtained using FwdMsk is the result of subtracting four recording traces,  
503 while only one recording trace is used in the HyperFit method. This methodological  
504 difference results in a vertical offset between the derived waveforms. Another potential  
505 factor that might have contributed to the vertical offset is the voltage difference between  
506 the resting physiological voltage before the eCAP response and the physiological voltage  
507 after the eCAP response measured at the end of the probe-only recording. Any voltage  
508 difference would have been captured in the artifact template obtained using HyperFit but

509 might have not been captured in the artifact template obtained using FwdMsk. However,  
510 there is no scientific evidence so far supporting the existence of a difference in  
511 physiological voltage before and after the eCAP response. In general, the characteristics  
512 of a voltage offset may have scientific or clinical value, but this remains unknown. In  
513 contrast, the eCAP amplitude has been used frequently in scientific and clinical studies.  
514 Therefore, we use the eCAP amplitude as a metric for comparing FwdMsk and HyperFit  
515 in this study.

516         The difference in the eCAP amplitude obtained using FwdMsk and HyperFit as a  
517 function of the estimated ARP is shown in Figure 9 for all 40 electrode locations tested.  
518 As can be observed in the figure, the difference in the eCAP amplitude was near zero for  
519 all electrode locations at which the estimated ARP was greater than 400  $\mu\text{s}$  (i.e., the MPI  
520 of the stimulus). In contrast, for electrode locations at which the estimated ARP was less  
521 than 400  $\mu\text{s}$ , the difference in the eCAP amplitude increased with decreasing ARP. These  
522 observations were confirmed by the results of statistical analyses. Specifically, there was  
523 not an effect of the artifact removal method on the eCAP amplitude when the estimated  
524 ARP was greater than 400  $\mu\text{s}$  ( $F_{1,38} = 0.19$ ,  $p = 0.666$ ). In contrast, there was a significant  
525 effect of the artifact removal method on the eCAP amplitude when the estimated ARP  
526 was less than 400  $\mu\text{s}$  ( $F_{1,38} = 13.67$ ,  $p < 0.001$ ). Finally, there was a significant effect of  
527 the estimated ARP on the difference in the eCAP amplitude when the estimated ARP was  
528 less than 400  $\mu\text{s}$  ( $F_{1,18} = 68.19$ ,  $p < 0.001$ ). These experimental results match the results  
529 expected based on theory.

530

531



532

533 **Figure 9.** The difference in electrically evoked compound action potential (eCAP)  
 534 amplitude obtained using the classic two-pulse forward masking artifact rejection  
 535 technique and the new hyperbola-fitting artifact subtraction technique at two electrode  
 536 locations per test ear in four ears of three pediatric cochlear implant (CI) users (blue filled  
 537 circles) and 16 ears of 14 adult CI users (red unfilled circles) as a function of the estimated  
 538 absolute refractory recovery period.

### 539 Test-retest Reliability

540 Estimates of intraclass correlation coefficients, along with the 95% confidence  
 541 intervals, for fitting-parameters and eCAP amplitudes obtained using HyperFit are  
 542 provided in Table 3. Clearly, there is excellent test-retest reliability for all fitting-  
 543 parameters and the eCAP amplitude obtained using HyperFit.

544



545 **Table 3.** Intraclass correlation coefficients for fitting-parameters and electrically evoked  
 546 compound action potential (eCAP) amplitudes obtained using the new method.

	Fitting parameters				eCAP amplitude
	a	b	c	d	
Estimate	0.987	0.998	0.999	0.991	0.995
Confidence Interval	[0.975, 0.993]	[0.997, 0.999]	[0.998, 1.000]	[0.985, 0.995]	[0.990, 0.998]

547

## 548 CONCLUSIONS

549 The underlying assumption of the classic two-pulse forward masking is invalid in up  
 550 to 45% of cases at high stimulation levels. Additionally, the eCAP amplitude obtained  
 551 using the forward masking technique is highly affected by varying the masker offset or  
 552 the masker-probe interval. Therefore, it is important to verify appropriate stimulation  
 553 settings (i.e., masker level and masker-probe interval) in any study that uses the forward  
 554 masking technique to calculate eCAP amplitudes. This is especially important in studies  
 555 that use the eCAP amplitude as a parameter for predicting neural health or as a correlate  
 556 to results of auditory perception. For cases in which the assumptions of forward masking  
 557 are met (i.e., +10 CL masker offset and  $ARP > MPI$ ), the eCAP amplitudes obtained using  
 558 forward masking are comparable to the eCAP amplitudes obtained using the new method.  
 559 Additionally, the eCAP amplitude calculated using the new method is consistent across  
 560 repeated measurements. Therefore, the new method presented in this report is a viable  
 561 alternative to the forward masking technique for obtaining artifact-free eCAPs in cathodic-  
 562 leading, single-pulse stimulation. Moreover, it has the advantage of reduced recording

563 time because it only requires one recording trace (vs. 4 required by the forward masking  
564 technique), and eCAPs can be recorded at higher stimulation levels because it does not  
565 require a strong masker pulse. The new method has currently only been validated for  
566 eCAPs evoked by single, cathodic-leading, biphasic pulses with fixed stimulation  
567 parameters (e.g., pulse phase duration = 25  $\mu$ s/phase, inter-phase gap = 7  $\mu$ s) in patients  
568 with normal inner-ear anatomy that were implanted with a Cochlear™ Nucleus® CI  
569 (Cochlear Ltd.). Research investigating the application of the new method with other  
570 stimulation parameters and testing paradigms (e.g., spread of excitation, refractory  
571 recovery, pulse-train stimulation) in various CI patient populations, along with optimization  
572 of the parameters of the new method (e.g., fitting-weights), is in process. Additionally,  
573 future studies will evaluate the relationships between eCAP metrics obtained using the  
574 new method (e.g., eCAP threshold) and behavioral measures (e.g., detection thresholds).  
575

576 **REFERENCES**

- 577 1. Brown CJ, Abbas PJ, and Gantz B. Electrically evoked whole-nerve action potentials:  
578 Data from human cochlear implant users. *The Journal of the Acoustical Society of*  
579 *America*. 1990;88(3):1385-91.
- 580 2. He S, Teagle HFB, and Buchman CA. The Electrically Evoked Compound Action  
581 Potential: From Laboratory to Clinic. *Frontiers in Neuroscience*. 2017;11:339.
- 582 3. Brochier T, Guérit F, Deeks JM, Garcia C, Bance M, and Carlyon RP. Evaluating and  
583 comparing behavioural and electrophysiological estimates of neural health in cochlear  
584 implant users. *Journal of the Association for Research in Otolaryngology*. 2021;22(1):67-  
585 80.
- 586 4. Jahn KN, and Arenberg JG. Electrophysiological Estimates of the Electrode-Neuron  
587 Interface Differ Between Younger and Older Listeners With Cochlear Implants. *Ear and*  
588 *Hearing*. 2020;41(4):948-60.
- 589 5. Jahn KN, and Arenberg JG. Identifying cochlear implant channels with relatively poor  
590 electrode-neuron interfaces using the electrically evoked compound action potential. *Ear*  
591 *and Hearing*. 2020;41(4):961-73.
- 592 6. Schwartz-Leyzac KC, Holden TA, Zwolan TA, Arts HA, Firszt JB, Buswinka CJ, et al.  
593 Effects of Electrode Location on Estimates of Neural Health in Humans with Cochlear  
594 Implants. *Journal of the Association for Research in Otolaryngology*. 2020;21(3):259-75.
- 595 7. Garcia C, Goehring T, Cosentino S, Turner RE, Deeks JM, Brochier T, et al. The  
596 Panoramic ECAP Method: Estimating Patient-Specific Patterns of Current Spread and  
597 Neural Health in Cochlear Implant Users. *Journal of the Association for Research in*  
598 *Otolaryngology*. 2021;22(5):567-89.

- 599 8. Skidmore J, Carter BL, Riggs WJ, and He S. The effect of advanced age on the  
600 electrode-neuron interface in cochlear implant users. *Ear and Hearing*. 2022;43(4):1300-  
601 15.
- 602 9. Skidmore J, Xu L, Chao X, Riggs WJ, Pellittieri A, Vaughan C, et al. Prediction of the  
603 functional status of the cochlear nerve in individual cochlear implant users using  
604 machine learning and electrophysiological measures. *Ear and Hearing*. 2021;42(1):180-  
605 92.
- 606 10. Schwartz-Leyzac KC, Colesa DJ, Buswinka CJ, Swiderski DL, Raphael Y, and Pfungst  
607 BE. Changes over time in the electrically evoked compound action potential (ECAP)  
608 interphase gap (IPG) effect following cochlear implantation in Guinea pigs. *Hearing  
609 Research*. 2019;383:107809.
- 610 11. Ramekers D, Benav H, Klis SFL, and Versnel H. Changes in the electrically evoked  
611 compound action potential over time after implantation and subsequent deafening in  
612 guinea pigs. *Journal of the Association for Research in Otolaryngology*. 2022.
- 613 12. Schwartz-Leyzac KC, Zwolan TA, and Pfungst BE. Using the electrically-evoked  
614 compound action potential (ECAP) interphase gap effect to select electrode stimulation  
615 sites in cochlear implant users. *Hearing Research*. 2021;406.
- 616 13. Müller-Deile J, Neben N, Dillier N, Büchner A, Mewes A, Junge F, et al. Comparisons of  
617 electrophysiological and psychophysical fitting methods for cochlear implants.  
618 *International Journal of Audiology*. 2023;62(2):118-28.
- 619 14. Chao X, Wang R, Luo J, Wang H, Fan Z, and Xu L. Relationship between electrically  
620 evoked compound action potential thresholds and behavioral T-levels in implanted  
621 children with cochlear nerve deficiency. *Scientific Reports*. 2023;13(1):4309.

- 622 15. Dong Y, Briaire JJ, Stronks HC, and Frijns JHM. Speech Perception Performance in  
623 Cochlear Implant Recipients Correlates to the Number and Synchrony of Excited  
624 Auditory Nerve Fibers Derived From Electrically Evoked Compound Action Potentials.  
625 *Ear and Hearing*. 2023;44(2):276-86.
- 626 16. Skidmore J, Oleson JJ, Yuan Y, and He S. The Relationship Between Cochlear Implant  
627 Speech Perception Outcomes and Electrophysiological Measures of the Electrically  
628 Evoked Compound Action Potential. *Ear and Hearing*. 2023;44(6):1485-97.
- 629 17. Skidmore J, Ramekers D, Colesa DJ, Schwartz-Leyzac KC, Pfungst BE, and He S. A  
630 broadly applicable method for characterizing the slope of the electrically evoked  
631 compound action potential amplitude growth function. *Ear and Hearing*. 2022;43(1):150-  
632 64.
- 633 18. He S, Skidmore J, Carter BL, Lemeshow S, and Sun S. Postlingually Deafened Adult  
634 Cochlear Implant Users With Prolonged Recovery From Neural Adaptation at the Level  
635 of the Auditory Nerve Tend to Have Poorer Speech Perception Performance. *Ear and*  
636 *Hearing*. 2022;43(6):1761-70.
- 637 19. Botros A, and Psarros C. Neural response telemetry reconsidered: II. the influence of  
638 neural population on the ECAP recovery function and refractoriness. *Ear and Hearing*.  
639 2010;31(3):380-91.
- 640 20. Geddes LA. Historical evolution of circuit models for the electrode-electrolyte interface.  
641 *Annals of Biomedical Engineering*. 1997;25(1):1-14.
- 642 21. Miller CA, Abbas PJ, Rubinstein JT, Robinson BK, Matsuoka AJ, and Woodworth G.  
643 Electrically evoked compound action potentials of guinea pig and cat: Responses to  
644 monopolar, monophasic stimulation. *Hearing Research*. 1998;119(1-2):142-54.

- 645 22. Bahmer A, Peter O, and Baumann U. Recording and analysis of electrically evoked  
646 compound action potentials (ECAPs) with MED-EL cochlear implants and different  
647 artifact reduction strategies in Matlab. *Journal of Neuroscience Methods*.  
648 2010;191(1):66-74.
- 649 23. Akhoun I, McKay CM, and El-Deredy W. Electrically evoked compound action potential  
650 artifact rejection by independent component analysis: technique validation. *Hearing*  
651 *Research*. 2013;302:60-73.
- 652 24. Spitzer P, Zierhofer C, and Hochmair E. Algorithm for multi-curve-fitting with shared  
653 parameters and a possible application in evoked compound action potential  
654 measurements. *BioMedical Engineering OnLine*. 2006;5:13.
- 655 25. Baudhuin JL, Hughes ML, and Goehring JL. A Comparison of Alternating Polarity and  
656 Forward Masking Artifact-Reduction Methods to Resolve the Electrically Evoked  
657 Compound Action Potential. *Ear and Hearing*. 2016;37(4):e247-55.
- 658 26. Miller CA, Abbas PJ, and Brown CJ. An improved method of reducing stimulus artifact in  
659 the electrically evoked whole-nerve potential. *Ear and Hearing*. 2000;21(4):280-90.
- 660 27. He S, Xu L, Skidmore J, Chao X, Jeng F-C, Wang R, et al. The effect of interphase gap  
661 on neural response of the electrically stimulated cochlear nerve in children with cochlear  
662 nerve deficiency and children with normal-sized cochlear nerves. *Ear and Hearing*.  
663 2020;41(4):918-34.
- 664 28. He S, Xu L, Skidmore J, Chao X, Riggs WJ, Wang R, et al. Effect of increasing pulse  
665 phase duration on neural responsiveness of the electrically stimulated cochlear nerve.  
666 *Ear and Hearing*. 2020;41(6):1606-18.
- 667 29. Xu L, Skidmore J, Luo J, Chao X, Wang R, Wang H, et al. The effect of pulse polarity on  
668 neural response of the electrically stimulated cochlear nerve in children with cochlear

- 669 nerve deficiency and children with normal-sized cochlear nerves. *Ear and Hearing*.  
670 2020;41(5):1306-19.
- 671 30. Luo J, Xu L, Chao X, Wang R, Pellittieri A, Bai X, et al. The effects of GJB2 or SLC26A4  
672 gene mutations on neural response of the electrically stimulated auditory nerve in  
673 children. *Ear and Hearing*. 2020;41(1):194-207.
- 674 31. Hughes ML. Electrically evoked compound action potential polarity sensitivity, refractory-  
675 recovery, and behavioral multi-pulse integration as potential indices of neural health in  
676 cochlear-implant recipients. *Hearing Research*. 2023;433:108764.
- 677 32. Hughes ML. Characterizing polarity sensitivity in cochlear implant recipients:  
678 Demographic effects and potential implications for estimating neural health. *Journal of*  
679 *the Association for Research in Otolaryngology*. 2022;23(2):301-18.
- 680 33. Hughes ML, Werff KRV, Brown CJ, Abbas PJ, Kelsay DMR, Teagle HFB, et al. A  
681 longitudinal study of electrode impedance, the electrically evoked compound action  
682 potential, and behavioral measures in Nucleus 24 cochlear implant users. *Ear and*  
683 *Hearing*. 2001;22(6):471-86.
- 684 34. Miller CA, Abbas PJ, and Robinson BK. Response properties of the refractory auditory  
685 nerve fiber. *Journal of the Association for Research in Otolaryngology*. 2001;2(3):216-  
686 32.
- 687 35. Tabibi S, Kegel A, Lai WK, Bruce IC, and Dillier N. Measuring temporal response  
688 properties of auditory nerve fibers in cochlear implant recipients. *Hearing Research*.  
689 2019;380:187-96.
- 690 36. Boulet J, White M, and Bruce IC. Temporal considerations for stimulating spiral ganglion  
691 neurons with cochlear implants. *Journal of the Association for Research in*  
692 *Otolaryngology*. 2016;17(1):1-17.

- 693 37. Hey M, Müller-Deile J, Hessel H, and Killian M. Facilitation and refractoriness of the  
694 electrically evoked compound action potential. *Hearing Research*. 2017;355:14-22.
- 695 38. Cartee LA, Miller CA, and van den Honert C. Spiral ganglion cell site of excitation I:  
696 Comparison of scala tympani and intrameatal electrode responses. *Hearing Research*.  
697 2006;215(1-2):10-21.
- 698 39. Ramekers D, Versnel H, Strahl SB, Klis SFL, and Grolman W. Recovery characteristics  
699 of the electrically stimulated auditory nerve in deafened guinea pigs: Relation to  
700 neuronal status. *Hearing Research*. 2015;321:12-24.
- 701 40. He S, Shahsavarani BS, McFayden TC, Wang H, Gill KE, Xu L, et al. Responsiveness of  
702 the electrically stimulated cochlear nerve in children with cochlear nerve deficiency. *Ear  
703 and Hearing*. 2018;39(2):238-50.
- 704 41. Morsnowski A, Charasse B, Collet L, Killian M, and Müller-Deile J. Measuring the  
705 refractoriness of the electrically stimulated auditory nerve. *Audiology and Neurotology*.  
706 2006;11(6):389-402.
- 707 42. Benjamini Y, and Hochberg Y. Controlling the false discovery rate: A practical and  
708 powerful approach to multiple testing. *Journal of the Royal Statistical Society: Series B  
709 (Methodological)*. 1995;57(1):289-300.
- 710 43. Chakravarthy K, Fitzgerald J, Will A, Trutnau K, Corey R, Dinsmoor D, et al. A Clinical  
711 Feasibility Study of Spinal Evoked Compound Action Potential Estimation Methods.  
712 *Neuromodulation: Technology at the Neural Interface*. 2022;25(1):75-84.
- 713 44. Botros A, van Dijk B, and Killian M. AutoNRT: an automated system that measures  
714 ECAP thresholds with the Nucleus Freedom cochlear implant via machine intelligence.  
715 *Artificial Intelligence in Medicine*. 2007;40(1):15-28.



- 716 45. Gartner L, Lenarz T, and Buchner A. Fine-grain recordings of the electrically evoked  
717 compound action potential amplitude growth function in cochlear implant recipients.  
718 *BioMedical Engineering OnLine*. 2018;17(1):140.
- 719 46. Shrout PE, and Fleiss JL. Intraclass Correlations - Uses in Assessing Rater Reliability.  
720 *Psychological Bulletin*. 1979;86(2):420-8.
- 721 47. Patrick JF, Busby PA, and Gibson PJ. The development of the Nucleus Freedom  
722 Cochlear implant system. *Trends in Amplification*. 2006;10(4):175-200.
- 723